Addition of postoperative chemotherapy to prevent or delay recurrence in patients newly diagnosed with localized uterine leiomyosarcoma and who have undergone complete tumor surgery.

Start Date01 Feb 2025

Sponsor / Collaborator

UNICANCER

[+5]

NCT06050434

/ CompletedNot ApplicableIIT

PROTraSarc Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients - A GISAR Sub-study

Chemotherapy with Trabectedin is an effective treatment for sarcoma patients in the second line setting or in first line for patients who are deemed unsuitable to receive anthracycline therapy. The prospective study will primarily investigate the PRO of Trabectedin rechallenge in patients with soft tissue sarcomas that had to discontinue initial Trabectedin treatment due to various reasons such as progression, side effects or surgery, as is commonly the case in real-life settings. Embedding this trial in the GISAR registry enables the evaluation of a large number of patients with long-term follow-up which allows multiple analyses regarding different questions that remain unanswered until today.

Start Date31 Oct 2023

Sponsor / Collaborator

Institut fr Klinische Krebsforschung IKF GmbH

[+1]

NCT04794127

/ RecruitingPhase 2IIT

A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)

This is a phase 2 study conducted in two sequential stages:
The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who achieved a stable disease after a minimum of 4 cycles of T alone. If a minimum required activity will be demonstrated from the first stage, the second stage of the study will be conducted;otherwise, the study will be stopped. The second stage is an Italian open-label, multicenter, randomized, double arm, phase II trial, aimed at evaluating the combination of T and P in myxoid liposarcoma and G1 or G2 dedifferentiated liposarcomas compared to the standard treatment with T alone. Patients will be randomized with a 1:1 ratio to treatments arms as specified below:
Control arm (A): T alone
Experimental arm (B): T in combination with P

Start Date02 Feb 2022

Sponsor / Collaborator

Fondazione Irccs Istituto Nazionale Dei Tumori

[+1]

100 Clinical Results associated with Trabectedin

100 Translational Medicine associated with Trabectedin

100 Patents (Medical) associated with Trabectedin

1,449

Literatures (Medical) associated with Trabectedin

01 Mar 2025·Annals of Surgical Oncology

Sarcoma: Last Year’s Practice Changing Papers

Review

Author: Gronchi, Alessandro ; van Houdt, Winan J

BACKGROUNDIn 2023 and 2024, a wide variety of new studies have been published in the field of soft tissue sarcomas, representing the enormous heterogeneity of sarcoma histotypes, anatomical location, treatment variability, and biological behavior.PATIENTS AND METHODSThis article summarizes the, in our view, seven most important publications in the field that will have an impact on the surgical practice and future treatment strategies of our patients.RESULTSIn the last year, we gained more insight in the genetic background of patients with sarcoma from a large Australian study, which will have an impact on future counseling and screening of our patients. Also, the role of radiotherapy in retroperitoneal liposarcoma became clearer in the combined STRASS-STREXIT study. Radiotherapy for extremity sarcomas can now also be done in a 3-week, hypofractioned manner, which is a major improvement for our patients. Furthermore, more evidence has been presented regarding the improved outcome of patients with retroperitoneal sarcoma when treated in high volume centers. Landmark studies with systemic treatment include the positive trial with nirogacestat in desmoid tumors, which have finally shifted the paradigm of desmoid treatment from surgery to systemic treatment. Also, the results of 2 phase 3 randomized controlled trials recently showed 1) that the combination of doxorubicin with trabectedin significantly improved progression free survival for patients with leiomyosarcoma when compared with doxorubicin alone and 2) that the combination of neoadjuvant pembrolizumab and radiotherapy followed by 1-yr adjuvant pembrolizumab significantly improved disease free survival for patients with primary localized undifferentiated pleomorphic sarcoma/myxofibrosarcoma or dedifferentiated/pleomorphic liposarcoma of the extremities or girdles.CONCLUSIONSKey papers from the last year informs us that management of soft tissues sarcoma is constantly improving, since more data became available to guide us in defining the best treatment strategies.

01 Mar 2025·In Vivo

HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction

Article

Author: Han, Qinghong ; Hayashi, Katsuhiro ; Tsuchiya, Hiroyuki ; Morinaga, Sei ; Kimura, Hiroaki ; Igarashi, Kentaro ; Kang, Byung Mo ; Hoffman, Robert M ; Higuchi, Takashi ; Bouvet, Michael ; Mizuta, Kohei ; Miwa, Shinji ; Yamamoto, Norio ; Demura, Satoru

BACKGROUND/AIMTrabectedin is a DNA-binding agent that has shown moderate efficacy for soft-tissue sarcomas. We have previously shown that methionine restriction enhances trabectedin efficacy on both parental and trabectedin-resistant HT1080 (TR-HT1080) cells in vitro The aim of the present study was to determine whether fibrosarcoma cells that acquire trabectedin resistance become more malignant but maintain sensitivity to methionine restriction in vivoMaterials and Methods: TR-HT1080 was established by culturing HT1080 cells in stepwise increasing concentrations of trabectedin. An in vitro wound-healing invasion assay was used to compare malignancy of HT1080 and TR-HT1080. In vivo, six groups were established: G1-G4 (TR-HT1080): G1, untreated control; G2, trabectedin treatment; G3, methionine-restricted diet; G4, methionine-restricted diet combined with trabectedin; G5, untreated control of parental HT1080; and G6, trabectedin treatment of parental HT1080.RESULTSThe IC₅₀ of trabectedin was previously determined to be 3.3 nM for the parental HT1080 cells and 42.9 nM for trabectedin-resistant HT1080 cells, representing a 13-fold increase. Wound-healing invasion assays in vitro showed a more rapid wound-closure ratio in TR-HT1080 cells than in parental cells, suggesting increased malignancy compared to the parental cells. The volume of untreated TR-HT1080 tumors grew more rapidly than that of HT1080 tumors, indicating a higher malignancy of TR-HT1080 tumors. The IC₅₀ of recombinant methioninase was previously determined as 0.75 U/ml for HT1080 and 0.93 U/ml for TR-HT1080 cells. Methionine restriction was highly effective on TR-HT1080 tumors, decreasing tumor growth by 4-fold.CONCLUSIONTR-HT1080 cells acquired high malignancy by in vitro selection for trabectedin resistance. However, methionine restriction overcame trabectedin resistance in vivo, strongly inhibiting tumor growth, which should be further investigated in the clinic.

01 Feb 2025·Japanese Journal of Radiology

Evaluation of a novel central venous access port for direct catheter insertion without a peel-away sheath

Article

Author: Tomita, Koji ; Uka, Mayu ; Okamoto, Soichiro ; Iguchi, Toshihiro ; Matsui, Yusuke ; Kawabata, Takahiro ; Hiraki, Takao ; Munetomo, Kazuaki ; Umakoshi, Noriyuki

AbstractPurposeThis study retrospectively evaluated the feasibility and safety of implanting a newly developed central venous access port (CV-port) that allows catheter insertion into a vein without the use of a peel-away sheath, with a focus on its potential to minimize risks associated with conventional implantation methods.Materials and methodsAll procedures were performed using a new device (P-U CelSite Port™ MS; Toray Medical, Tokyo, Japan) under ultrasound guidance. The primary endpoint was the implantation success rate. The secondary endpoints were the safety and risk factors for infection in the early postprocedural period (< 30 days).ResultsWe assessed 523 CV-port implantations performed in a cumulative total of 523 patients (240 men and 283 women; mean age, 61.6 ± 13.1 years; range, 18–85 years). All implantations were successfully performed using an inner guide tube and over-the-wire technique through 522 internal jugular veins and one subclavian vein. The mean procedural time was 33.2 ± 10.9 min (range 15–112 min). Air embolism, rupture/perforation of the superior vena cava, or hemothorax did not occur during catheter insertion. Eleven (2.1%) intraprocedural complications occurred, including Grade I arrhythmia (n = 8) and subcutaneous bleeding (n = 1), Grade II arrhythmia (n = 1), and Grade IIIa pneumothorax (n = 1). Furthermore, 496 patients were followed up for ≥ 30 days. Six early postprocedural complications were encountered (1.1%), including Grade IIIa infection (n = 4), catheter occlusion (n = 1), and skin necrosis due to subcutaneous leakage of trabectedin (n = 1). These six CV-ports were withdrawn, and no significant risk factors for infection in the early postprocedural period were identified.ConclusionThe implantation of this CV-port device demonstrated comparable success and complication rates to conventional devices, with the added potential benefit of eliminating complications associated with the use of a peel-away sheath.

News (Medical) associated with Trabectedin

28 Feb 2025

·www.fiercepharma.com

Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses slate of new drugs and label expansions

For Eisai and Biogen, the European Medicines Agency’s Committee for Medicinal Products for Human Use’s decision to stick by its previous call on Leqembi now punts the final approval verdict back to the European Commission, which is the ultimate authority on whether a drug scores marketing authorization in the EU. Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), drugmakers are celebrating a bevy of endorsements for big-name meds.Over the course of the sit-down, which ran from Monday through Thursday, the CHMP recommended four new drugs for approval, teed up another 16 potential label expansions and—in a major win for Eisai and Biogen—reaffirmed the positive opinion on the Alzheimer’s disease drug Leqembi (lecanemab) it first issued in November, according to the agency’s meeting summary Friday.For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on whether a drug scores marketing authorization in the EU.Despite Leqembi winning the CHMP’s favor in November—albeit in a somewhat restricted patient population—the European regulator last month said it would honor the EC’s request to consider new safety data on the antibody that surfaced after the initial thumbs-up, Biogen explained in a Friday press release.“The safety profile of lecanemab reported in clinical practice in the United States, Japan and other countries after launch is consistent with that in the approved labels, and no new safety signals are identified,” Biogen said of the situation last month. The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene. Patients with two copies of the gene are at greater risk of brain swelling or bleeding side effects known as amyloid-related imaging abnormalities, according to trial data. Elsewhere, the CHMP this week advanced four new drugs for potential European approvals. Those are: Takeda’s immunoglobulin drug Deqsiga, Regeneron’s multiple myeloma antibody Lynozyfic, Krystal Biotech’s dystrophic epidermolysis bullosa gene therapy Vyjuvek and Accord Healthcare’s generic drug trabectedin, which has been endorsed in advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.As for proposed label expansions, the CHMP endorsed new uses for drugs from Vertex, Novartis, AbbVie, Eli Lilly and many other companies.In Lilly’s case, the regulator recommended approval for the company’s BTK inhibitor Jaypirca to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) who’ve already tried another medication from the same class.In addition to the new positive opinion in CLL, the drug also boasts a conditional European nod in mantle cell lymphoma, Lilly noted in a press release.AbbVie, for its part, got the CHMP’s backing in its bid to expand Rinvoq’s reach into the inflammatory disease giant cell arteritis, while Novartis’ Fabhalta received the agency’s blessing to treat adults with C3 glomerulopathy (C3G). C3G is an ultrarare kidney disease—often striking when people are young—that currently lacks any approved treatment options, Novartis said Friday.Other major label expansions that passed muster with the CHMP include those for Vertex’s Kaftrio and Kalydeco in combination to treat cystic fibrosis patients 2 and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene, plus a bid to expand the use of Valneva’s chikungunya vaccine Ixchiq to provide active immunization for kids starting at age 12. Notably, several drugmakers withdrew applications from the CHMP.Sanofi, for example, pulled the plug on efforts to score a European label expansion for Dupixent to treat moderate to severe chronic spontaneous urticaria in adults and adolescents, according to the committee's update. Plus, Spanish biotech HIPRA withdrew the application for an adapted version of its COVID-19 vaccine Bimervax targeting an updated strain of the SARS-CoV-2 virus.

Drug ApprovalVaccine

28 Feb 2025

·endpts.com

CHMP recommends Regeneron, Novartis drugs that still await FDA approval

The European Medicines Agency’s human medicines committee (CHMP) has recommended four new drugs for approval, including Regeneron’s Lynozyfic for the treatment of relapsed and refractory multiple myeloma. The recommendation is a step forward for Regeneron in Europe after the FDA last August rejected its drug in the US over manufacturing issues . The FDA has set a new decision deadline of July 10. CHMP also suggested that the European Commission approve Krystal Biotech’s Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a genetic skin condition. The other recommendations were for Accord Healthcare’s generic trabectedin and Takeda’s immunoglobulin drug Deqsiga. The European Commission has the final authority over new drug approvals, but it typically follows CHMP’s recommendations. CHMP also recommended 16 label expansions, including Novartis’ Fabhalta for the treatment of rare kidney disease C3 glomerulopathy (C3G), which currently has no approved medicines. Fabhalta is currently approved by the EMA as a treatment for hemolytic anemia in patients with a blood disease called paroxysmal nocturnal hemoglobinuria. The FDA is reviewing Fabhalta for C3G, with a decision date expected by June . The agency was supposed to hold a meeting for the kidney drug this week but it was canceled for unknown reasons . CHMP said that no changes need to be made to Eisai and Biogen’s Alzheimer’s drug Leqembi, after the commission had requested a review of the drug’s market authorization in January. A review was requested after CHMP gave a positive opinion on the drug to treat Alzheimer’s patients with only one or no copy of the ApoE4 gene in November 2024. CHMP had previously rejected Leqembi in July 2024. CHMP’s other label expansion recommendations include:

Drug ApprovalAccelerated Approval

28 Feb 2025

·pharmamar.com

PharmaMar Group announces financial resultsfor fiscal year 2024

PharmaMar Group's total revenue as of December 31st, 2024, grew by 11% over 2023 to €174.9 million. Royalties from sales increased by 18% to €61.3 million. Revenue from license agreements rose by 38% to €46.5 million. R&D investment amounted to €103.5 million. EBITDA reached €13.0 million, compared to €2.1 million recorded in 2023. PharmaMar Group closed 2024 with a net profit of €26.1 million. PharmaMar Group (MSE: PHM) closed fiscal year 2024 with a total revenue of €174.9 million, representing an 11% increase compared to the previous year. Recurring revenue, which includes net sales plus royalties received from partners, grew 3% year-over-year, reaching €127.9 million as of year-end 2024. As of December 31st, 2024, total oncology sales amounted to €66.5 million, compared to €70.7 million in the previous year. This difference is due to fluctuations in Yondelis® (trabectedin) sales and the reversal of the provision recorded in 2023 on Zepzelca® (lurbinectedin) revenue from the compassionate use program in France. Total lurbinectedin sales in 2024 reached €35.3 million, including revenue from the compassionate use program—mainly in France—of €22.2 million, commercial sales in Europe of €6.4 million, and active ingredient sales of €6.7 million. In comparison, in 2023, total lurbinectedin sales amounted to €36.7 million, a figure that included an accounting adjustment of €10.4 million due to the reversal of a provision for unapplied discounts. Excluding this adjustment, total lurbinectedin sales in 2024 would have shown an approximate 34% growth. Total Yondelis® revenue in 2024 grew 15%, reaching €54.4 million. This figure includes Yondelis® sales, which totaled €31.3 million in 2024 compared to €34.1 million in the previous year, as well as royalties and license agreement revenue, detailed below. Trabectedin sales include commercial sales in Europe, which reached €18.0 million in 2024, compared to €26.1 million the previous year, and active ingredient sales to partners, which amounted to €13.3 million in 2024, up from €7.9 million in 2023. The increase in active ingredient sales to partners has offset the pricing impact caused by the entry of generics in Europe. As of December 31st, 2024, PharmaMar Group's oncology royalty revenue reached €61.3 million, representing an 18% increase compared to the previous year. This growth was driven by royalties received from Jazz Pharmaceuticals for lurbinectedin sales in the U.S., which grew 15% to €55.8 million. In addition to the royalties received from Jazz Pharmaceuticals through December 31st, 2024, trabectedin royalties from partners in the U.S. and Japan amounted to €5.2 million, representing a 36.4% increase over total trabectedin royalties received in 2023. Regarding non-recurring revenue from license agreements, as of the end of 2024, this totaled €46.5 million, reflecting a 38.5% increase compared to the previous year. Of this total, €23 million corresponds to deferred revenue recognition from the 2019 agreement with Jazz Pharmaceuticals for lurbinectedin, a similar figure to the previous year. Additionally, €17.9 million came from payments related to the trabectedin license agreement with Janssen (compared to €9.4 million as of December 2023), and €4.4 million corresponded to revenue from the lurbinectedin license agreement with Luye. PharmaMar Group’s R&D investment in 2024 grew 4% compared to the previous year, reaching €103.5 million. Of the total R&D investment, the oncology segment saw a 13% increase, reaching €94.4 million. This growth was mainly driven by the advancement of ongoing clinical trials during 2024, such as LAGOON (a Phase III trial for second-line small cell lung cancer treatment) and SaLuDo (a Phase IIb/III trial for leiomyosarcoma treatment). The LAGOON trial completed patient enrolment in the last quarter of 2024. Additionally, the Company continues investing in the clinical development of early-stage molecules. In this regard, two Phase II clinical trials are ongoing with ecubectedin, along with Phase I trials with PM534 and PM54, all focused on solid tumor treatment. Thanks to revenue growth in 2024, PharmaMar Group reached an EBITDA of €13.0 million, compared to €2.1 million in 2023. The Company’s net profit increased to €26.1 million at the end of 2024, compared to €1.1 million in 2023. As of December 31st, 2024, PharmaMar Group reported a cash and cash equivalents balance of €157 million, with a total financial debt of €47.8 million, reflecting an increase of nearly €8 million compared to the previous year, due to the acquisition of a €15 million long-term bank loan. As a result, the net cash position at the year-end stood at €109 million. PharmaMar will host a conference call with analysts and investors on February 28th, 2025, at 1:30 PM (CET). To join the conference call, it is recommended to register at this link to receive access numbers and a personalized PIN. To access the call without prior registration, use the following numbers: +34 919 01 16 44 (Spain), +1 646 233 4753 (USA) o +44 20 3936 2999 (UK). Conference number: 883194. Additionally, the presentation will be available for live streaming at this link.

Phase 1License out/inFinancial StatementPhase 2Phase 3

100 Deals associated with Trabectedin

External Link

KEGG	Wiki	ATC	Drug Bank
D06199	Trabectedin	L01CX01	DB05109

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Leiomyosarcoma	United States	Janssen Products LP	23 Oct 2015
Soft Tissue Neoplasms	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2015
Liposarcoma	Canada	Valeo Pharma, Inc.	05 Aug 2010
Soft Tissue Sarcoma	South Korea	Verto Korea	22 Apr 2008
Platinum-Sensitive Ovarian Carcinoma	Norway	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	Liechtenstein	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	European Union	Pharma Mar SA	17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma	Iceland	Pharma Mar SA	17 Sep 2007
Sarcoma	Norway	Pharma Mar SA	17 Sep 2007
Sarcoma	European Union	Pharma Mar SA	17 Sep 2007
Sarcoma	Liechtenstein	Pharma Mar SA	17 Sep 2007
Sarcoma	Iceland	Pharma Mar SA	17 Sep 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent ovarian cancer	Discovery	Brazil	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	Taiwan Province	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	China	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	Russia	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	Poland	Pharma Mar SA	01 Apr 2005
Recurrent ovarian cancer	Discovery	Poland	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	Australia	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	France	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Apr 2005
Recurrent ovarian cancer	Discovery	United Kingdom	Pharma Mar SA	01 Apr 2005
Recurrent ovarian cancer	Discovery	Canada	Pharma Mar SA	01 Apr 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04979442 (MANTRA, CTgov)	Phase 3	Dedifferentiated Liposarcoma	175	Trabectedin	gcmsitnnus(ynzkrnaown) = kezadsddvg jvliyfthru (tyqbfkbhta, witxrdqwds - xijjgpnmma) View more	-	14 Jan 2025
709 (SITC2024)	Not Applicable	Malignant glioma of brain	9	Trabectedin	jbbqgeglpt(yxetwbqkpk) = bthmghpiic ifdqgfefmk (ygdidufgja )	Positive	05 Nov 2024
				Anti-PD1 immunotherapy	jbbqgeglpt(yxetwbqkpk) = utwdrzjeob ifdqgfefmk (ygdidufgja )
NCT03127215 (AIO-STS \| TF-0117 \| ass, ESMO2024) Manual	Phase 2	Solid tumor DNA repair deficiencies	117	Trabectedin olaparib (TrO)TrO)	(zcywztpvvp) = ntuywfjvpg nicsghyblh (fotcmdkqgx ) View more	Negative	15 Sep 2024
				Physician’s choice (PC)	(zcywztpvvp) = spdgsggqfo nicsghyblh (fotcmdkqgx )
NCT03138161 (SAINT, ESMO2024) Manual	Phase 2	Soft Tissue Sarcoma First line	97	TrabectedinIpilimumabnivolumab	(emgsuaiwgd) = tfemrxxkik wwlqwqbdwd (srfrazcjev, 5.247 - 9.353) View more	Positive	14 Sep 2024
NCT03886311 (TNT, ESMO2024) Manual	Phase 2	Leiomyosarcoma \| Liposarcoma	29	Talimogene Laherparepvec nivolumabtrabectedin	(rmaqndjkzp) = uwickxnnat emmyymjvhe (mrymrcjtvb, 14.9 - 28.9) View more	Positive	14 Sep 2024
ESMO2024	Not Applicable	Soft Tissue Sarcoma Second line \| Third line	207	Trabectedin	(kgplczxubq) = tooyadvroq udkzthqlgs (cgtoghyfnb ) View more	Positive	14 Sep 2024
				Trabectedin + Radiotherapy	(kgplczxubq) = neevimirkx udkzthqlgs (cgtoghyfnb ) View more
NCT02997358 (LMS04, Pubmed \| N Engl J Med) Manual	Phase 3	Leiomyosarcoma Maintenance \| First line	150	Doxorubicin+Trabectedin	(qgtssjzpwk) = biwuoiwayz mufbrxhrbh (tdwroqvaec, 10 - 16) View more	Positive	05 Sep 2024
				Doxorubicin	(qgtssjzpwk) = vbannwfpgg mufbrxhrbh (tdwroqvaec, 4 - 7) View more
NCT04076579 (CTgov)	Phase 2	Metastatic osteosarcoma	29	Olaparib+Trabectedin (Cohort 1)	(rjlyrbeqht) = yytvntcwon lmagkfaggg (ntakqiytvc, ajthomihfy - niljjsspss) View more	-	29 Jul 2024
				Olaparib+Trabectedin (Cohort 2)	(rjlyrbeqht) = grtododmxo lmagkfaggg (ntakqiytvc, vesbsdfyrp - jwrrcirlex) View more
NCT04067115 (SARC037, ASCO2024) Manual	Phase 2	Recurrent Ewing Sarcoma \| Refractory Ewing Sarcoma	16	Trabectedin 1 irinotecan	(rqmefyznwt) = fqhotoptln gmoqmkqdgv (johepxfyxv, 18.3 - 77.7) View more	Positive	24 May 2024
GEIS study (ASCO2024)	Not Applicable	Locally Advanced Soft Tissue Sarcoma ERCC1 \| BRCA1 \| HMGA1 ... View more	140	Trabectedin	(lzsotgxaqk) = lrnsnjdmax moizyrffvw (mcfgtgxlis, 5.1 - 11.3)	Positive	24 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis